

Regeneus

Cryoshot partner

Partner for CryoShot a vote of confidence

Pharma & biotech

The agreement with one of the top five veterinary pharma companies to collaborate on the development of CryoShot Canine is recognition of the good progress that Regeneus has made developing its regenerative medicine products and cancer vaccines. At its recent AGM, Regeneus confirmed that it anticipates winning the much bigger prize of a manufacturing and development partner in Japan for its Progenza off-the-shelf human stem cell product by Q116. We maintain our valuation of A\$106m (A\$0.51/share) ahead of this potential re-rating catalyst.

Year end	Revenue (A\$m)	PBT* (A\$m)	EPS* (A\$)	DPS (A\$)	P/E (x)	Yield (%)
06/14	2.0	(7.5)	(0.05)	0.0	N/A	N/A
06/15	1.9	(6.6)	(0.03)	0.0	N/A	N/A
06/16e	1.4	(3.9)	(0.02)	0.0	N/A	N/A
06/17e	1.7	(4.0)	(0.02)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding intangible amortisation & exceptional items.

Top five vet pharma partners CryoShot development

Regeneus has partnered with an un-named top five veterinary pharma company to develop CryoShot Canine. Regeneus and the partner will jointly fund a randomised pre-pivotal study in 80 client-owned dogs with arthritis, with results anticipated in Q316. The partner has an option to exclusively license the CryoShot technology at the completion of the study in exchange for an upfront fee, development milestone payments and a royalty on all CryoShot sales. The results of the study will be used to design a pivotal US FDA trial, which would be funded by the partner.

Progenza: Partnering discussions and clinical trial

Dosing of the first cohort of 10 patients with knee osteoarthritis in the first-in-human trial of Progenza is currently underway. A review of safety data from cohort 1 is expected before the end of CY15, with enrolment of the final cohort to start in Q116. Positive safety data would be an important milestone towards the company's goal to finalise one or more deals with potential manufacturing, clinical and marketing partners for Progenza in Japan before the end of Q116.

Human cancer vaccine trial underway

The first patient in the ACTIVATE trial of the RGSH4K human cancer vaccine was safely dosed in October. Enrolment in the 21-person trial is expected to be completed in Q316.

Valuation: Unchanged at A\$106m or A\$0.51/share

Our valuation is unchanged at A\$106m or A\$0.51/share. The company had A\$1.5m cash at 30 September and received an A\$3.4m R&D incentive payment in October, giving it a cash runway to Q3 CY16 at an average burn rate of A\$1.7m/quarter. We estimate the company needs additional funds of A\$2m for working capital in FY16 and A\$3m in FY17. These funds could come from partnering deals, or potentially a capital raise. With the company continuing to trim costs, we have reduced forecast operating losses by 13%, 11% and 6% in FY16, FY17 and FY18 respectively.

2 December 2015

Price **A\$0.11**

Market cap **A\$23m**

US\$0.7/A\$

Net cash (A\$m) at 30 June 2015 3.0

Shares in issue 208.9m


Free float 56%

Code RGS

Primary exchange ASX

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs (15.4) 0.0 (24.1)

Rel (local) (16.8) (3.7) (25.9)

52-week high/low A\$0.21 A\$0.09

Business description

Regeneus is an Australia-based clinical-stage regenerative medicine company developing innovative cell-based therapies for the human and animal health markets. It is focused on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

Next events

Progenza cohort 1 safety data Q415

Partner or JV for Progenza in Japan Q116

Kvax canine osteosarcoma trial results Q116

Analysts

Dennis Hulme +61 (0)2 9258 1161

Christian Glennie +44 (0)20 3077 5727

healthcare@edisongroup.com

[Edison profile page](#)

Japan licence deal for Progenza a potential catalyst

Regeneus is in advanced discussions to secure a manufacturing and development partner for Progenza in Japan. A number of large Japanese companies are seeking access to technology that will allow them entry into the regenerative medicine field to take advantage of the favourable regulatory environment, which includes a fast-track approval pathway. Regeneus has encountered genuine interest from a number of potential partners, and anticipates finalising these discussions before the end of Q116.

Upfront fees and milestone payments from the potential deal could offer a source of non-dilutive funding for its ongoing work on new product development. In addition, we would expect a partner to either fully or partly cover the costs of the planned Phase II trial of Progenza in patients with osteoarthritis of the knee.

Regeneus has treated the first cohort of 10 patients in its Phase I trial of Progenza, with the second of the two dose cohorts expected to begin enrolling subjects in Q116. Trial participants receive ultrasound-guided injections of either Progenza or placebo directly into their arthritic knee joint. In each cohort eight patients will be treated with Progenza and two will receive a placebo injection.

High potency cell identification technology adds to product development capability

Regeneus has in-licensed technology from Macquarie University that may allow it to develop more potent cell products that secrete higher levels of desired cytokines and growth factors. Acquiring this technology fits neatly with the company's strategy to focus on its expertise in early-stage product development.

The technology for the first time enables researchers to identify as well as select individual live stem cells that are able to secrete high levels of cytokines. The technology could potentially allow Regeneus to develop designer stem cell products where the cytokine production profile has been matched to the disease being treated.

Importantly, the technology is applicable to a wide range of cell types and is not restricted to mesenchymal stem cells or cells derived from adipose tissue. There are near-term applications of the technology for developing analysis kits for research and diagnostic markets.

While the development team has shown that high-secreting cells selected using the technology maintain that profile through several cell culture passages, there would still be plenty of challenges remaining in ensuring that the cells maintained the desirable cytokine secretion profile when scaled up for commercial manufacture. The in-licensed technology provides a useful tool that could be used in this process to help identify the cell culture conditions that best maintain the cytokine-secreting capacity of the selected cells.

Pre-pivotal trial of CryoShot Canine underway

A randomised pre-pivotal study of CryoShot Canine in 80 client-owned dogs with arthritis began on 2 November at the University of Pennsylvania School of Veterinary Medicine, under the leadership of Professor Dorothy Brown. The trial will assess the change in levels of pain and dysfunction in arthritic dogs by validated questionnaires and force plate analysis following intraarticular injection of CryoShot or placebo.

The trial will be jointly funded by Regeneus and its un-named top five veterinary pharma partner. At the completion of the trial (results expected in Q316), the partner will have an option to exclusively license the CryoShot technology. The results of the study will inform the design of a pivotal US FDA

trial, which would be funded by the partner, and may also provide additional validation for new IP developed by Regeneus that could improve the likelihood of success when using CryoShot.

Trial of Kvac in dogs with lymphoma to support commercial uptake

Regeneus began recruiting subjects in a trial of its Kvac cancer vaccine in 45 dogs with lymphoma in November. The double-blind, placebo-controlled trial, to be conducted by veterinary oncologists at the Small Animal Specialist Hospital in Sydney, Australia, will use Kvac together with chemotherapy to seek to extend remission times in dogs that initially respond to chemotherapy. Lymphoma is the most commonly treated cancer in dogs; remission typically lasts 8-10 months with chemotherapy, with a median survival of about one year.

The trial of Kvac in dogs with osteosarcoma conducted with Dr Phil Bergman of VCA, the largest veterinary services group in the US, has completed recruitment and is expected to report results in Q116.

As Kvac is an autologous vaccine it can be made commercially available in Australia and the US without specific regulatory approval. Over 100 dogs with more than 14 different cancers have been treated with Kvac in Australia. However, while there are no further regulatory hurdles to be cleared, widespread commercial uptake will depend on positive efficacy data in clinical trials such as those currently underway in osteosarcoma and lymphoma. Regeneus continues to explore global commercial partnering opportunities for Kvac.

Valuation

Our valuation of Regeneus is unchanged at A\$106m, or A\$0.51 per share. Our sum-of-the-parts DCF valuation model is summarised in Exhibit 1, with key assumptions displayed in Exhibit 2.

Our valuation model applies a standard 12.5% discount rate and includes 30 June 2015 net cash of A\$3.0m. We assume that product sales peak six years after market launch, plateau at that level for five years, and decline at 10% per year. For simplicity, we do not include upfront and milestone payments from any future licensing deals, and instead assume that the full value of the product will be paid as a royalty. We note that there is a risk-adjustment applied to each programme, appropriate to the status of development, and our valuation is not a price target but a fair value for the stock today. Risk adjustments would unwind as programmes advance through clinical studies, gain regulatory approvals, secure commercial partners, etc.

Progenza is the key long-term value driver, with peak sales estimated at A\$1.75bn. Therefore, clinical and regulatory progress over the next few years would significantly de-risk the product, which currently has a 15% probability of success.

Exhibit 1: Regeneus valuation model

Product	Setting	Region	Status	Launch	NPV (A\$m)	Peak sales (A\$m)	Probability of success	Economic interest	rNPV (A\$m)	rNPV per share (A\$)
Progenza	Human - OA	Australia/ Japan/EU/US	Phase I	2020 (Japan); 2024 (EU/US/Aus)	443.1	1,754	15%	Royalty (20%)	62.4	0.30
Human cancer vaccine	Solid tumours	WW	Phase I	2024	62.1	500	15%	13% net royalties	8.3	0.04
CryoShot	Animal - OA	Australia	Pre- registration field trials	2012	10.8	7	30%-100%	Operating profit (40%- 60%)	1.9	0.01
CryoShot	Animal - OA	EU	Registration studies	2020	24.9	45	30%	30% effective royalty rate	6.8	0.03
CryoShot	Animal - OA	USA	Registration studies	2020	31.3	54	30%	30% effective royalty rate	8.4	0.04
Kvax canine vaccine	Dog cancer	WW	Marketed (Aus) Marketing studies (US)	2016 (Aus); 2018	36.6	43	40%	30% effective royalty rate	14.6	0.07
Portfolio total					615.7				102.5	0.49
Net cash (as of 30 June 2015)									3.0	0.01
Overall valuation									105.5	0.51

Source: Edison Investment Research

Exhibit 2: Regeneus valuation assumptions

Product	Setting	Region	Status	Key assumptions
Progenza	Human - OA	Australia/ Japan/EU/US	Phase I	Prevalence ~10% of >55yrs in all regions; 10% suitable candidates for treatment; 10% Progenza peak market share (2029 in US/EU); A\$5,000 per procedure (A\$3,750 in EU).
Human cancer vaccine	Solid tumours	WW	Phase I	\$500m peak sales indicative potential (non-cancer specific); 13% net royalty rate after 4%-7% pay-away to Northern Sydney Local Health District (NSLHD).
CryoShot	Animal - OA	Australia	Pre- registration field trials	~4,500 small animal vet practitioners; 5% peak penetration in 2023, 75x per year, at A\$250 per dose; sliding scale or probability (100% near-term to 30% post-2020).
CryoShot	Animal - OA	EU	Registration studies	~90,000 small animal vet practitioners; peak penetration in 2025, with 3% use CryoShot, 50x per year, at A\$250 per dose; 30% probability with studies/partners to complete.
CryoShot	Animal - OA	US	Registration studies	~50,000 small animal vet practitioners; peak penetration in 2025, with 5% use CryoShot, 75x per year, at A\$250 per dose; 30% probability with studies/partners to complete.
Kvax canine vaccine	Dog cancer	WW	Marketed (Aus) Marketing studies (US)	~540/100,000 annual incidence of dog cancers; ~860,000 cancers US/EU/Japan/Aus; assume 10% get drug/vaccine treatment; 25% peak Kvax penetration of treated dogs by 2023 (=21,600 Kvax treatments); A\$2,000 per treatment course; 40% probability with studies/partners to complete.

Source: Edison Investment Research

Sensitivities

With regard to Progenza, CryoShot, Kvax and the human cancer vaccine – the key long-term valuation drivers – we have assumed timely clinical and commercial progress in multiple regions, which should be achievable, but any delays/setbacks would have a negative impact on our valuation. A commercialisation deal for the secretions technology represents potential upside, as we do not currently include secretions products in our valuation model.

Financials

Regeneus reported a loss of A\$6.6m for FY15 (ended 30 June 2015). The result included one-off costs totalling A\$1.6m incurred in winding-down the HiQCell business. Net cash used in operating activities in the first quarter of FY16 was A\$1.6m. With the company continuing to trim costs, we have reduced forecast operating expenses, reducing forecast losses by 13%, 11% and 6% in FY16, FY17 and FY18 respectively. Regeneus had A\$1.5m cash at 30 September, and received an A\$3.4m R&D incentive rebate in October. Under the Australian government's R&D tax incentive scheme, approximately 45% of eligible R&D costs can be reimbursed. The combined total of A\$4.9m gives it a cash runway to Q416 at an average burn rate of A\$1.7m/qtr. We estimate that an additional A\$2m funds would provide sufficient working capital to fund operations until the FY16 R&D rebate payment (our estimate A\$2.5m) is received in October 2016, with a further A\$4m required in FY17. These funds could come from pending partnering deals, or potentially a capital raise. In our forecasts we assume that this funding is provided by long-term debt, as per our standard policy, and we assign A\$2m to long-term debt in FY16 and A\$3m in both FY17 and FY18.

Exhibit 3: Financial summary

Year end 30 June	AASB	AASB	AASB	AASB	AASB
PROFIT & LOSS					
Revenue	2,003	1,900	1,374	1,679	3,119
Cost of Sales	(621)	(915)	(155)	(224)	(468)
Gross Profit	1,381	985	1,219	1,454	2,652
R&D expenses	(5,758)	(4,945)	(3,956)	(4,154)	(3,946)
SG&A expenses	(6,756)	(6,250)	(3,632)	(3,773)	(3,973)
EBITDA	(10,800)	(9,805)	(6,090)	(6,144)	(4,983)
Operating Profit (before GW and except.)	(11,118)	(10,191)	(6,357)	(6,466)	(5,259)
Intangible Amortisation	(16)	(19)	(12)	(7)	(9)
Exceptionals	0	0	0	0	0
Other (includes R&D tax credit)	3,767	3,418	2,453	2,492	2,368
Operating Profit	(7,367)	(6,792)	(3,916)	(3,980)	(2,900)
Net Interest	(157)	186	(0)	(55)	(55)
Profit Before Tax (norm)	(7,507)	(6,588)	(3,905)	(4,029)	(2,946)
Profit Before Tax (IFRS)	(7,523)	(6,607)	(3,916)	(4,036)	(2,955)
Tax benefit	0	0	0	0	0
Profit After Tax (norm)	(7,507)	(6,588)	(3,905)	(4,029)	(2,946)
Profit After Tax (IFRS)	(7,523)	(6,607)	(3,916)	(4,036)	(2,955)
Average Number of Shares Outstanding (m)	166.5	208.9	209.4	210.4	211.4
EPS - normalised (A\$)	(0.05)	(0.03)	(0.02)	(0.02)	(0.01)
EPS - IFRS (A\$)	(0.05)	(0.03)	(0.02)	(0.02)	(0.01)
Dividend per share (A\$)	0.00	0.00	0.00	0.00	0.00
BALANCE SHEET					
Fixed Assets	3,170	2,451	2,642	2,501	2,548
Intangible Assets	30	26	34	49	60
Tangible Assets	1,362	892	1,074	920	956
Investments	1,778	1,533	1,533	1,533	1,533
Current Assets	7,089	7,128	5,446	4,995	5,461
Stocks	206	99	72	105	218
Debtors	134	67	67	67	67
Cash	2,635	3,013	2,322	1,800	2,276
Other	4,114	3,950	2,985	3,025	2,900
Current Liabilities	(1,698)	(1,260)	(1,260)	(1,260)	(1,260)
Creditors	(921)	(781)	(781)	(781)	(781)
Short term borrowings	0	0	0	0	0
Other	(777)	(478)	(478)	(478)	(478)
Long Term Liabilities	(253)	(48)	(2,048)	(5,048)	(8,048)
Long term borrowings	0	0	(2,000)	(5,000)	(8,000)
Other long term liabilities	(253)	(48)	(48)	(48)	(48)
Net Assets	8,308	8,272	4,780	1,190	(1,298)
CASH FLOW					
Operating Cash Flow	(6,239)	(5,923)	(2,221)	(3,333)	(2,192)
Net Interest	0	0	0	0	0
Tax	0	0	0	0	0
Capex	(1,176)	(208)	(470)	(189)	(332)
Acquisitions/disposals	0	8	0	0	0
Financing	10,209	6,168	0	0	0
Dividends	0	0	0	0	0
Other	4,900	0	0	0	0
Net Cash Flow	7,694	45	(2,691)	(3,522)	(2,523)
Opening net debt/(cash)	4,366	(2,635)	(3,013)	(322)	3,200
HP finance leases initiated	0	0	0	0	0
Other	(693)	333	0	0	0
Closing net debt/(cash)	(2,635)	(3,013)	(322)	3,200	5,724

Source: Regeneus accounts, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Regeneus and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2015. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.